Botanix Pharmaceuticals Limited
ASX:BOT.AX
0.41 (AUD) • At close September 16, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Botanix Pharmaceuticals Limited |
Symbool | BOT.AX |
Munteenheid | AUD |
Prijs | 0.415 |
Beurswaarde | 752,826,600 |
Dividendpercentage | 0% |
52-weken bereik | 0.115 - 0.445 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Vincent P. Ippolito |
Website | https://www.botanixpharma.com |
An error occurred while fetching data.
Over Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)